---
title: "MedBot: Accelerating Overseas Growth and Path to 2026 Breakeven Support Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280822179.md"
description: "DBS analyst Nico Chen has maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, setting a price target of HK$33.00. The rating is supported by the company's rapid overseas growth and improving financials, particularly with its laparoscopic surgical robot, Toumai, which is gaining significant market share. Chen anticipates the company will reach breakeven by 2026, driven by increasing sales and better cost management, despite potential geopolitical challenges."
datetime: "2026-03-27T15:35:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280822179.md)
  - [en](https://longbridge.com/en/news/280822179.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280822179.md)
---

# MedBot: Accelerating Overseas Growth and Path to 2026 Breakeven Support Buy Rating

DBS analyst Nico Chen maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H today and set a price target of HK$33.00.

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Nico Chen has given his Buy rating due to a combination of factors including the company’s rapid scale-up in overseas markets and improving financial profile. MedBot’s flagship laparoscopic surgical robot, Toumai, has quickly become one of the top two products globally by order volume, with overseas orders and installations rising strongly and now contributing the bulk of total sales, supported by a clear cost advantage versus the leading competing system.

At the same time, losses are narrowing sharply as revenue grows and operating expenses fall as a percentage of sales, helped in part by more disciplined R&D spending and better cost control as the business scales. Chen expects the company to move toward breakeven around 2026, and he bases his HKD33.0 target price on a discounted cash flow valuation, citing accelerating overseas order momentum and the anticipated break-even point as key share price catalysts despite potential headwinds from global geopolitical tensions.

According to TipRanks, Chen is a 4-star analyst with an average return of 8.2% and a 53.73% success rate. Chen covers the Healthcare sector, focusing on stocks such as Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, Amgen, and AptarGroup.

### Related Stocks

- [02252.HK](https://longbridge.com/en/quote/02252.HK.md)

## Related News & Research

- [MicroPort MedBot Proposes New Share Scheme to Replace Existing Incentive Plans](https://longbridge.com/en/news/286423581.md)
- [MicroPort MedBot Sets 2026 AGM With New Capital Mandates on the Table](https://longbridge.com/en/news/286426445.md)
- [Maxim Group Sticks to Its Buy Rating for Newsmax Inc. Class B (NMAX)](https://longbridge.com/en/news/286573867.md)
- [EagleRock Land Nets $333 Million From Class A Share Offering Priced at $18.50](https://longbridge.com/en/news/286969275.md)
- [Figure AI had one of its robots race a human to sort packages. It lost.](https://longbridge.com/en/news/286883540.md)